Introduction {#s1}
============

Primary ciliary dyskinesia (PCD) is a genetic, heterogeneous disease caused by absence and/or dysfunction of cilia \[[@C1]\]. Its prevalence is estimated to be around 1 in 10 000, but it is underdiagnosed \[[@C2]\]. It can affect ciliated cells throughout the body and lead to numerous manifestations, primarily in the respiratory system \[[@C3]\]. Most patients suffer from chronic and recurrent upper respiratory infections from early in life, which can lead to lung damage and bronchiectasis as the disease progresses \[[@C1], [@C4]\].

Lung function is one of the most important predictors of overall survival among both healthy individuals and patients with chronic lung disease \[[@C5]\]. Spirometry, which is widely available, is the easiest and most common method of testing pulmonary function. Spirometric indices, primarily forced expiratory volume in 1 s (FEV~1~), are used to monitor progression and describe severity in chronic respiratory diseases such as cystic fibrosis or chronic obstructive pulmonary disease \[[@C6]--[@C8]\]. In PCD patients, several studies have reported results of lung function measurements; however, their findings are contradictory, ranging from normal lung function to significant impairment. Most studies have focused on paediatric or young adult patients and reports from older patients are rare. Data on sex differences are also scarce, although evidence is growing that a number of pulmonary diseases affect females and males differently \[[@C9]\]. A detailed overview and comparison of existing studies of lung function is necessary to inform PCD research about existing and improved use of spirometry, and to determine where more evidence is needed in the study and treatment of PCD.

This systematic review and meta-analysis therefore identifies all published studies presenting lung function in patients with PCD, and it summarises spirometric indices reported in those studies. We also identify differences in these spirometric indices between male and female patients and between paediatric and adult patients.

Methods {#s2}
=======

The protocol we developed for the systematic review is summarised here. We followed the PRISMA guidelines for reporting \[[@C10]\].

Search strategy {#s2a}
---------------

We searched PubMed, Embase and Scopus with no restriction of language or study design for studies published between January 1980 and February 2017 that described lung function in patients with PCD (Orphanet classification ORPHA:244).

We tested multiple search terms to decide on the most appropriate term for each database. We selected the most concise terms that identified the largest number of studies.

PubMed: (("kartagener syndrome"\[Title/Abstract\] OR "primary ciliary dyskinesia"\[Title/Abstract\] OR "ciliary motility disorders"\[MeSH Terms\]) AND ("lung function" OR "respiratory function" OR "pulmonary function" OR "lung volume" OR "forced vital capacity" OR "forced expiratory volume" OR "FEV" OR "FEV1" OR "spirometry" OR "wash out" OR "Follow-Up Studies" \[MeSH\] OR "Respiratory Function Tests" \[MeSH\])).

Embase: "primary ciliary dyskinesia":ab,ti OR "kartagener":ab,ti OR "kartageners":ab,ti OR "ciliary motility disorder":ab,ti AND ("lung function" OR "respiratory function" OR "pulmonary function" OR "lung volume" OR "spirometry" OR "fev" OR "forced expiratory volume" OR "forced vital capacity" OR "fev1" OR "plethysmography" OR "wash out").

Scopus: ((TITLE-ABS-KEY("primary ciliary dyskinesia")) OR (TITLE-ABS-KEY("kartagener")) OR (TITLE-ABS-KEY("ciliary motility disorder"))) AND (("wash out") OR (("lung function") OR ("lung volume") OR ("respiratory function") OR ("pulmonary function") OR ("forced vital capacity" OR fvc) OR ("forced expiratory volume") OR ("spirometry"))).

After identifying all eligible studies, we checked for additional citations in their reference lists. We used Endnote X5 (Thomson Reuters, Philadelphia, PA, USA) citation manager.

Definition of PCD patients {#s2b}
--------------------------

The diagnosis of PCD has changed over the period from 1980 to present \[[@C11], [@C12]\]. The studies we included have a wide range of patient inclusion criteria, ranging from patients with a clinical diagnosis (in most cases Kartagener syndrome) to those with positive results from tests that have varied with diagnostic consensus at the time of each study: electron microscopy, light or high-speed video-microscopy, nasal nitric oxide (nNO) and genetic testing.

Study selection {#s2c}
---------------

We included studies reporting lung function of patients with PCD that had a study population of 10 or more patients. We excluded animal studies and those that were not original, studies that described diagnostic test results or genetics, but lacked information on lung function, and those that reported on other rare ciliary syndromes, such as Joubert syndrome.

We initially screened publication titles and abstracts. From our experience with PCD literature \[[@C3]\], we realised that many studies of PCD patients report lung function measurements without explicitly articulating this in the title or abstract. Thus, we also screened the full text of original clinical studies of PCD patients even if lung function was not mentioned in the title or abstract. After reading the full text of all potentially eligible studies, the final decision on inclusion was made by two independent reviewers, one with extensive experience in systematic reviews and knowledge of the disease. In case of disagreement, a consensus decision was reached after discussion. During the final step of inclusion, we excluded studies that did not report any spirometric indices and conference abstracts that lacked full text.

Overlapping study population {#s2d}
----------------------------

To avoid including the same patients multiple times in our review, we identified all studies that appeared to share the same study population. We compared the author list, country of origin and department where the study took place. In case we noticed a considerable overlap in the study population between two or more studies, we always included in the quantitative synthesis the study that was published most recently and included information on a larger number of patients. When two studies were published ≥10 years apart, we included both since we believed there would be little chance of significant overlap. Where the extent of possible overlap was not clear, we contacted the study investigators for clarification.

Data extraction {#s2e}
---------------

We used Epidata version 3.1 ([www.epidata.dk](http://www.epidata.dk)) to extract information from all studies, including those with overlapping populations. We extracted 1) author- and publication-specific information, which included author names, journal and year of publication, country, and centre of corresponding author; 2) study characteristics, which included years the study was carried out, study design, inclusion and exclusion criteria, study population size, country where the study took place, type of clinic, age of participants, and age stratification of reported lung function measurements; and 3) information on spirometry of PCD patients. For spirometry, we extracted all information reported on lung function measurements, including values of spirometric indices and information on equipment used for spirometry, quality control measures and reference values.

Meta-analysis {#s2f}
-------------

We performed meta-analyses of FEV~1~ and forced vital capacity (FVC), the most commonly reported spirometry indices, using a DerSimonian--Laird random effects model \[[@C13], [@C14]\], and assessed the heterogeneity (*I*^2^) between studies \[[@C15]\]. We assessed possible differences in lung function between children and adults by performing separate subgroup meta-analyses in adults and children. Studies that did not report FEV~1~ and FVC separately for adults and children or in which information on age was not available were excluded from this subgroup analysis.

We then investigated reasons for heterogeneity by fitting meta-regression models. We considered the following explanatory factors one at a time: period of publication (before 1997, 1997--2007, after 2007), number of patients included in the study (\<20, 21--50, 51--100, \>100 patients), retrospective or prospective study design, reference values used for spirometry (references using ≥5000 subjects, \<5000 subjects, no information) \[[@C16]\], pulmonary function test quality control (based on European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines, used the best out of three valid measurements, no information available) and whether spirometry was the main study outcome (no, yes) \[[@C17]\].

Statistical analysis was performed with R version 3.1.2 ([www.r-project.org](www.r-project.org)) using the package meta version 4.3-2, specifically the commands metagen and metareg.

Results {#s3}
=======

Search {#s3a}
------

After excluding duplicates appearing in more than one of the databases (PubMed, Embase and Scopus), our initial search produced 664 articles ([figure 1](#F1){ref-type="fig"}). We screened the titles and abstracts of these, and excluded 501 articles. Among the remaining 163 studies, 37 were either conference abstracts only or it was not possible to find the full text. After reading the full text of the remaining 126 studies, we excluded another 102 articles ([figure 1](#F1){ref-type="fig"}), including 34 that had overlapping study populations \[[@C18]--[@C50]\]. Finally, we included 24 studies reporting spirometric indices of PCD patients in the meta-analysis.

![Flowchart describing the selection procedure.](00231-2018.01){#F1}

Study characteristics and information on spirometry {#s3b}
---------------------------------------------------

[Table 1](#TB1){ref-type="table"} lists the 24 studies and their characteristics \[[@C4], [@C51]--[@C73]\]. The articles encompassed a total of 1179 patients with a mean (range) number of 49 (13--158) patients per study. Most studies were relatively small, with 18 of the 24 including less than 50 patients ([table 2](#TB2){ref-type="table"}). Nearly all studies originated from paediatric or adult pulmonology departments, or from specialised PCD centres. 17 were single-centre studies. 15 were published in the last 10 years (after 2007). 15 came from Europe, six from Asia and three were from North or South America. Seven studies included only children (age \<18 years), three only adults (age ≥18 years) and 14 studies had populations of mixed age consisting mainly of children with a few adults.

###### 

Detailed characteristics of included studies describing spirometric indices of primary ciliary dyskinesia patients, stratified by age group of patients

  **First author \[ref.\]**                                     **Country**         **Year of publication**   **Patients n**                   **Age years**                    **Type of study**   **Study design**              **Diagnostics**              **Symptoms stratified by age**   **Longitudinal data**   **FEV**~1~   **FVC**
  ------------------------------------------------------ ------------------------- ------------------------- ---------------- ------------------------------------------------ ------------------- ------------------ --------------------------------------- -------------------------------- ----------------------- ------------ ---------
  **Children**                                                                                                                                                                                                                                                                                                                      
   A[l]{.smallcaps} S[aadi]{.smallcaps} \[[@C51]\]             Saudi Arabia                  2013                   22                         10.86±3.09^\#^                      Prospective       Case--control                    EM+HFVM                                NA                           −                 \+          −
   D[avis]{.smallcaps} \[[@C55]\]                               USA/Canada                   2015                  118                          8 (5--11)^¶^                       Prospective        Case series             EM or genetic analysis                         NA                           −                 \+          −
   G[okdemir]{.smallcaps} \[[@C58]\]                              Turkey                     2014                   24                          12.9±2.7^\#^                       Prospective       Clinical trial              EM or Kartagener                            NA                           −                 \+         \+
   K[aradag]{.smallcaps} \[[@C61]\]                                 UK                       1999                   21                          10.8±3.2^\#^                      Retrospective      Case--control                   EM, HFVM                                NA                           −                 \+         \+
   K[oh]{.smallcaps} \[[@C62]\]                                    Korea                     2000                   19                         12 (7--16)^+^                       Prospective       Clinical trial                     EM                                   NA                           −                 \+          −
   M[aglione]{.smallcaps} \[[@C63]\]                       Denmark, Italy and UK             2014                  158                       8.7 (4.2--17.4)^§^                   Retrospective          Cohort               According to consensus                         NA                          \+                 \+         \+
   P[aff]{.smallcaps} \[[@C68]\]                              The Netherlands                2013                   25                      10.7 (7.1--14.5)^¶^                    Prospective       Case--control            According to consensus                         NA                           −                 \+          −
  **Adults**                                                                                                                                                                                                                                                                                                                        
   F[rija-]{.smallcaps}M[asson]{.smallcaps} \[[@C57]\]            France                     2017                   78                      34.8 (28.6--47.1)^¶^                  Retrospective       Case series       EM, genetic analysis or Kartagener                   NA                          \+                 \+         \+
   H[orvath]{.smallcaps} \[[@C60]\]                                 UK                       2003                   14                           35±4.6^\#^                        Prospective       Case--control                   EM, HFVM                                NA                           −                 \+         \+
   M[ossberg]{.smallcaps} \[[@C65]\]                              Sweden                     1983                   24                         30 (19--47)^§^                      Prospective        Case series               Clinical suspicion                           NA                           −                 \+          −
  **Both children and adults**                                                                                                                                                                                                                                                                                                      
   A[mirav]{.smallcaps} \[[@C52]\]                                Israel                     2016                   13                         10 (5--43)^¶^                      Retrospective       Case series      All tests, including genetic analysis                 −                            −                 \+          −
   B[oon]{.smallcaps} \[[@C53]\]                                  Belgium                    2014                  122                      17.7 (9.5--28.1)^¶^                   Retrospective       Case series           EM, HFVM, genetic analysis                       −                            −                 \+         \+
   C[ohen-]{.smallcaps}C[ymberknoh]{.smallcaps} [@C54]            Israel                     2014                   14                          15.9±8.6^\#^                      Retrospective       Case series         EM, HFVM, nNO, genetic analysis                    −                            −                 \+          −
   E[llerman]{.smallcaps} \[[@C56]\]                              Denmark                    1997                   24                          21±13.6^\#^                        Prospective        Case series                      HFVM                                  \+                          \+                 \+         \+
   H[ellinckx]{.smallcaps} \[[@C59]\]                             Belgium                    1998                   11                           15.2±7^\#^                        Prospective        Case series                    EM, HFVM                                \+                          \+                 \+          −
   M[ahut]{.smallcaps} \[[@C64]\]                                 France                     2006                   16                        13.5 (12--17)^¶^                    Retrospective       Case series                  Clinical, EM                              \+                           −                 \+          −
   N[oone]{.smallcaps} \[[@C4]\]                              USA and Canada                 2004                   78         Adults: 36 (19--73)^+^; children: 8 (1--17)^+^      Prospective        Case series           EM, HFVM, genetic analysis                       \+                           −                 \+          −
   N[yilas]{.smallcaps} \[[@C66]\]                        Germany and Switzerland            2017                   49                          14.7±6.6^\#^                       Prospective       Case--control                   All tests                               −                            −                 \+         \+
   O[lm]{.smallcaps} \[[@C67]\]                                   Brazil                     2011                   10                          13.4±4.7^\#^                       Prospective       Case--control                    EM+HFVM                                \+                           −                 \+         \+
   P[ifferi]{.smallcaps} \[[@C69]\]                                Italy                     2015                   45                         14 (22.25)^¶^                       Prospective       Case--control                 EM, HFVM, nNO                             −                            −                 \+         \+
   S[hah]{.smallcaps} \[[@C70]\]                                    UK                       2016                  118                        23.5 (10--36)^¶^                    Retrospective       Case series           EM, HFVM, nNO, 2% clinical                       −                           \+                 \+          −
   T[olusakow]{.smallcaps} \[[@C71]\]                             Germany                    1981                   21                            3--43^ƒ^                        Retrospective       Case series               Clinical suspicion                           −                            −                 \+         \+
   V[allet]{.smallcaps} \[[@C72]\]                                France                     2013                   41                          6 (3--11)^¶^                      Retrospective       Case series                    EM, HFVM                                −                           \+                 \+         \+
   Y[iallouros]{.smallcaps} \[[@C73]\]                            Cyprus                     2015                   20                          0.1--58.4^ƒ^                      Retrospective       Case series                 EM or HFVM+nNO                             \+                          \+                 \+         \+

FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; EM: electron microscopy; HFVM: high-frequency video-microscopy; NA: not applicable; nNO: nasal nitric oxide. Age is reported in different formats depending on the available information: ^\#^: mean±[sd]{.smallcaps}; ^¶^: median (interquartile range); ^+^: median (range); ^§^: mean (range); ^ƒ^: range.

###### 

Characteristics of included studies describing spirometry indices of primary ciliary dyskinesia patients

  -------------------------------------------------------------------------------------------------------------- -----------
  **Total studies**                                                                                               24 (100)
  **Study size**                                                                                                 
   ≤20 patients                                                                                                    8 (33)
   21--50 patients                                                                                                 10 (42)
   51--100 patients                                                                                                 2 (8)
   \>100 patients                                                                                                  4 (17)
  **Number of centres**                                                                                          
   Single centre                                                                                                   17 (71)
   Multicentre                                                                                                     7 (29)
  **Publication period**                                                                                         
   ≤1996                                                                                                            2 (8)
   1997--2007                                                                                                      7 (29)
   ≥2008                                                                                                           15 (63)
  **Study region**                                                                                               
   Europe                                                                                                         15 (62.5)
   Asia                                                                                                            6 (25)
   North and South America                                                                                        3 (12.5)
  **Age of participants**                                                                                        
   Children \<18 years                                                                                             7 (29)
   Adults ≥18 years                                                                                                3 (13)
   Children and adults                                                                                             14 (58)
  **Study design**                                                                                               
   Retrospective                                                                                                   11 (46)
   Prospective                                                                                                     13 (54)
  **Diagnostics performed**                                                                                      
   Diagnosis based only on strong clinical suspicion                                                                2 (8)
   Diagnosis based on EM or a combination of tests in most patients; few only on strong clinical suspicion^\#^     3 (13)
   Diagnosis based on EM or a combination of tests in all patients^\#^                                             19 (79)
  **Spirometry indices reported**                                                                                
   FEV~1~                                                                                                         24 (100)
   FVC                                                                                                             12 (50)
  **Information for different age groups**                                                                        6 (43)^¶^
  **Longitudinal information**                                                                                     8 (33)
  -------------------------------------------------------------------------------------------------------------- -----------

Data are presented as n (%). EM: electron microscopy; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity. ^\#^: combination of the following: EM, nasal nitric oxide, high-frequency video-microscopy or light microscopy, or genetic analysis. ^¶^: of 14 studies including children and adults.

PCD diagnosis was established in different ways. 19 studies assessed ciliary ultrastructure using electron microscopy and/or a combination of one or more of nNO, video-microscopy and genetics according to available consensus at the time of each publication ([table 2](#TB2){ref-type="table"}). In three of the 24 studies, the majority of patients were similarly diagnosed on the basis of ciliary ultrastructure, although a small proportion of the patients were diagnosed based only on strong clinical suspicion, mainly Kartagener syndrome. In two, older studies, all patients were diagnosed based on strong clinical suspicion, again primarily Kartagener syndrome.

All studies reported FEV~1~ measurements and half of them also reported FVC measurements. How investigators reported lung function measurements varied. The most commonly reported spirometric indices were FEV~1~ and FVC, presented as mean and standard deviation of percent predicted values. In studies in which FEV~1~ and FVC were reported differently or important information was not reported, we contacted the investigators for additional data. Among the 14 studies that included both paediatric and adult patients, only six of the 14 reported lung function results stratified by age groups. Only four of the 24 studies reported FEV~1~ and FVC as z-scores. Eight also reported other lung function measurements such as plethysmography and multiple-breathe washout techniques or exhaled breath analysis techniques. Investigators used a variety of different spirometry reference values depending on the year of publication; 10 out of the 24 studies did not report which references were used for the calculation of the percent predicted values. 12 of the studies reported that spirometry was performed based on the ERS/ATS guidelines, while in five more the best of three acceptable spirometry measurements was chosen. The remaining seven studies did not report on quality measures of spirometry. Only seven of the 24 studies included longitudinal measurements of lung function.

[S](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00231-2018.figures-only#fig-data-supplementary-materials)[upplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00231-2018.figures-only#fig-data-supplementary-materials) presents the characteristics of all included studies and studies with overlapping populations.

Forced expiratory volume in 1 s {#s3c}
-------------------------------

Reported FEV~1~ values varied significantly between the studies and mean FEV~1~ % pred ranged from 51% to 96%. Weighted mean FEV~1~ % pred in the 24 studies was 75% (95% CI 69--80%) with a heterogeneity of *I*^2^=96% ([figure 2](#F2){ref-type="fig"}). Results remained the same when we excluded from the meta-analysis the two studies having only clinically diagnosed patients. In the subgroup meta-analyses, including the 16 studies with information on age groups, eight studies reported FEV~1~ measurements in patients aged ≥18 years and 13 reported FEV~1~ measurements in children aged \<18 years. In adults, mean FEV~1~ % pred values ranged from 44% to 79% with a weighted mean value of 63% (95% CI 57--69%) and *I*^2^=91% ([figure 3](#F3){ref-type="fig"}). In children, mean FEV~1~ % pred values ranged from 73% to 96% with a weighted mean value of 81% (95% CI 78--83%) and *I*^2^=78% ([figure 3](#F3){ref-type="fig"}).

![Forced expiratory volume in 1 s (FEV~1~) in primary ciliary dyskinesia patients: forest plot showing the heterogeneity and weighted mean value of FEV~1~ % pred in the included studies.](00231-2018.02){#F2}

![Forced expiratory volume in 1 s (FEV~1~) in primary ciliary dyskinesia patients by age group: forest plot showing the heterogeneity and weighted mean value of FEV~1~ % pred in the included studies.](00231-2018.03){#F3}

Forced vital capacity {#s3d}
---------------------

In the 13 studies including FVC % pred results, reported values ranged from 66% to 92%. Weighted mean FVC % pred was 83% (95% CI 78--89%) with a heterogeneity of *I*^2^=94% ([figure 4](#F4){ref-type="fig"}). In the subgroup meta-analyses, we included four studies reporting FVC measurements for patients aged ≥18 years and six studies of children aged \<18 years. In adults, mean FVC % pred values ranged from 70% to 94% with a weighted mean value of 79% (95% CI 70--88%) and *I*^2^=89% ([supplementary figure S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00231-2018.figures-only#fig-data-supplementary-materials)). In children, mean FVC % pred values ranged from 77% to 90% with a weighted mean value of 85% (95% CI 80--90%) and *I*^2^=72% ([supplementary figure S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00231-2018.figures-only#fig-data-supplementary-materials)).

![Forced vital capacity (FVC) in primary ciliary dyskinesia patients: forest plot showing the heterogeneity and weighted mean value of FVC % pred in the included studies.](00231-2018.04){#F4}

Meta-regression {#s3e}
---------------

Meta-regressions showed that the explanatory factors explained only a small part of the between-studies variance for all symptoms. Studies published after 2007 reported higher mean values of FEV~1~ and FVC (both p=0.01). Another factor that explained part of the heterogeneity was the reference values for spirometry. Studies that did not report the reference values they used reported lower mean values for both FEV~1~ and FVC (p=0.003 and p=0.002, respectively). Mean FEV~1~ was lower in studies that did not include any information on pulmonary function test quality control (p=0.02). Detailed results of the meta-regression models are presented in [supplementary table S2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00231-2018.figures-only#fig-data-supplementary-materials).

Differences between males and females {#s3f}
-------------------------------------

Only two of the 24 studies compared lung function of male and female patients. In a large cohort of French adult patients, the spirometric indices of females were lower than those of males at the end of the study and the annual decline of FEV~1~ was also greater in females \[[@C57]\]. In contrast, no difference by sex was reported in a large British adult cohort \[[@C70]\].

Longitudinal data {#s3g}
-----------------

Finally, although a preponderance of PCD studies made cross-sectional assessments, seven of the 24 studies in our meta-analysis followed lung function of PCD patients longitudinally, as did a further five of the 34 studies in which we observed overlapping populations. The differing designs and follow-up times of these 12 longitudinal studies disallow pooling their results in a meta-analysis. However, we offer a qualitative overview of the findings reported in them.

Four studies reported that most patients had stable spirometric indices (FEV~1~ and FVC) during respective short-term or longer follow-ups \[[@C56], [@C59], [@C63], [@C72]\]. Four other more recent studies including adult patients reported important declines of FEV~1~ and/or FVC \[[@C27], [@C40], [@C57], [@C70]\]. A study of the Danish national cohort of PCD patients \[[@C25]\] reported at least a 10% decrease in FEV~1~ % pred in one-third of the patients, although great variation in lung function was observed after follow-up. In the British adult cohort, an ultrastructural defect was associated with lung function decline: patients with a microtubular defect reported a steeper decline \[[@C70]\], a finding that was not consistent with the results of a study of 60 French children with PCD \[[@C72]\]. Larger national or multicentre studies reported no association between lung function decline and age of diagnosis \[[@C25], [@C63]\]. Preliminary results from 71 patients included in the international PCD registry showed an annual mean decline of 0.59% in FEV~1~ % pred and of 0.39% in FVC % pred \[[@C40]\]. Recent, smaller studies have evaluated the effect of managing lung function of PCD patients with, for example, lobectomy \[[@C73]\] and endoscopic sinus surgery \[[@C18]\], without observing significant differences in lung function decline.

Discussion {#s4}
==========

This is the first systematic review of lung function measurements of PCD patients. FEV~1~ was lower in adults than children, but studies report a wide range of FEV~1~ and FVC values. This heterogeneity is not accounted for by available explanatory factors. Of the 664 studies originally identified, only 9% reported spirometry of PCD patients; 34 of the studies had overlapping study populations. Most studies were small, with a mean of 49 patients per study, and less than half of the studies that included both children and adults reported lung function stratified by age. Only two studies examined differences by sex. Reports of spirometric indices were associated with the period of publication, provision of lung function reference values and information on spirometry quality control. Not surprisingly, newer studies reported higher lung function values.

The main strength of this study is in its methodology. We performed the search without language restrictions and screened the full text of every identified clinical study with an original study population, even if lung function was not explicitly mentioned in the abstract. This ensured that we included studies that a custom approach might miss. We contacted primary investigators of the included studies to acquire spirometric indices in a consistent form in order to pool them in meta-analyses, and we separated our results for paediatric and adult patients. We also accounted for heterogeneity in the results by performing a meta-regression with all available explanatory factors. However, we were not able to include other factors that were possibly known but not published in the studies. These include genetic variations in studied populations, which are known to result in varying disease severity \[[@C52], [@C55]\], other indicators of disease severity such as imaging data to assess structural changes in the lungs, and less well-documented clinical factors such as compliance, adherence to therapy, age at diagnosis, and varying standards in clinical surveillance and treatment (*e.g.* history of lobectomy and clinical status at the time of measurement).

We restricted our search to studies published since 1980 for several reasons. Many things have changed in understanding and characterising PCD since it was first described by Kartagener in the early 1930s. Older studies are often not available online or do not have an abstract in the online databases. In addition, clinical studies of PCD before 1980 were mostly case reports or small studies with less than 10 patients that were not eligible for our review.

Our review undoubtedly reflects the weaknesses of its included studies, most of which suffered from significant selection bias. Its important limitations involve the differences in study designs and aims of the included studies that might have directly influenced the lung function assessment of study populations. Most studies used a convenience patient sample and did not describe how the participants were selected. It is possible that in some cases patients with more severe respiratory problems were recruited whose lung function might be more impaired. We did not perform a risk of bias assessment for the studies included in this review. We expected all studies to suffer from moderate to serious risk, which is common in these types of studies, especially in rare diseases, *e.g.* small studies mainly based on case series of patients. Our most important limitation is that we could not compare the spirometric indices of the included studies using the same reference values and, ideally, use z-scores for FEV~1~ and FVC. Unfortunately, the majority of included studies reported percent predicted values derived from a variety of references. To address this issue, we tested the particular lung function reference as a possible explanatory factor in the heterogeneity in our meta-regression.

We do not expect significant diagnostic misclassification in the included studies, mainly because most studies adhered to consensus guidelines and were published more recently \[[@C74]\]. However, misclassification bias is still possible, especially for the older studies. When we repeated our meta-analyses excluding the two studies with only clinical diagnoses the results did not change. As most studies suffered from the same design flaws, we did not apply any quality assessment criteria to decide which studies to include in our meta-analysis.

Due to the considerable heterogeneity, the calculated mean weighted values of percent predicted FEV~1~ and FVC should be interpreted with caution. The meta-analysis was performed to quantify the variability in reported spirometric indices and not to give valid estimates. The possible explanatory factors we tested failed to explain this heterogeneity. Still, some factors contributed to explaining differences in FEV~1~ and FVC in the included studies. Publication year may be indicative of differences in awareness and disease diagnosis as well as changes in standardisation of treatment and routine surveillance of patients. Recent studies are more likely to have used modern diagnostic approaches, and include more patients who are correctly diagnosed and patients who have less severe disease and more genetic variations compared with older studies. They also usually include patients treated with more modern treatment protocols, and use newer and more correct spirometry reference values. Studies that did not report information on quality control of spirometry data or lung function reference values might have had less strict protocols for lung function measurements compared with studies that reported this information in detail. Although it was not possible to pool the studies including repeated lung function measurements and study disease progression over time, the reported percent predicted FEV~1~ was lower in adult patients compared with children. On the one hand, this could support the progression of lung disease into adulthood; on the other hand, differences between adults and children might also reflect differences in disease management or diagnosis over the years.

Methodological variability in the studies we included could not explain the heterogeneity in lung function. We believe that this heterogeneity is caused by factors that could not be tested in a meta-analysis given the information that we had available (*e.g.* genetic factors, differences in disease management, factors related to the variability of study inclusion criteria, and details on the performance and evaluation of lung function measurements). This heterogeneity in lung function measurements goes hand in hand with the heterogeneity we reported in our previous review on the clinical manifestations of PCD, which highlights the limitations of published studies to describe the full clinical spectrum of PCD \[[@C3]\]. However, the results of both reviews underline the possibility of distinctly different disease phenotypes, which also are observed in other chronic respiratory diseases \[[@C75]--[@C77]\]. This is further supported by reports that link specific ultrastructural defects and genetic mutations with more severe lung disease. In a study of North American children with PCD, those with an absence of inner dynein arms in conjunction with central apparatus defects and microtubular disorganisation associated with *CCDC39* and *CCDC40* mutations had lower spirometric indices compared with other PCD patients \[[@C55]\]. Data from a smaller case series of Israeli patients, analysed together with data from previous case reports, found that patients with *CCNO* mutations showed rapid deterioration of lung function \[[@C52], [@C78], [@C79]\].

All these findings demonstrate the need for collaborative, prospective studies that use standardised protocols for spirometry and international up-to-date reference values. To meet this need, together with a network of international collaborators we are developing a standardised, disease-specific instrument for patient follow-up and prospective data collection \[[@C80], [@C81]\]. At the same time, researchers in centres around the world are conducting a prospective multicentre observational study of variability of lung function in PCD patients (PROVALF-PCD) that will provide information on how FEV~1~ itself varies in individual stable PCD patients \[[@C82]\].

Conclusions {#s4a}
-----------

Spirometric indices of PCD patients vary significantly between published studies, which not only suggests the possibility of methodological differences between centres, but also real differences in disease expression. Detailed characterisation of different PCD phenotypes in studies that use standardised outcome measures and protocols, international up-to-date reference values, and, ideally, phenotype--genotype associations are needed to explain this variability and to better understand the natural history of PCD.
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